@article{TLCR29328,
author = {Alice Mogenet and Pascale Tomasini and Laurent Greillier and Fabrice Barlesi},
title = {Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {Suppl 4},
year = {2019},
keywords = {},
abstract = {Metastatic non-small cell lung cancer (NSCLC) remains the first cause of cancer-related death worldwide (1). Recent progress in the medical treatment of NSCLC have been focusing on molecular alterations. Anaplastic lymphoma kinase (ALK) rearrangements are found in about 3% to 5% of lung adenocarcinomas in western countries, more frequently non-smokers and younger patients than most NSCLC.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/29328}
}